BBIBP-CorV(国药)COVID-19疫苗在多发性硬化症患者中的安全性:来自伊朗的报告

S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough
{"title":"BBIBP-CorV(国药)COVID-19疫苗在多发性硬化症患者中的安全性:来自伊朗的报告","authors":"S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough","doi":"10.14302/issn.2690-4837.ijip-22-4342","DOIUrl":null,"url":null,"abstract":"Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. \nMethod: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated.\nResults: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. \nConclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.\n\nKeywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety","PeriodicalId":325366,"journal":{"name":"International Journal of Infection Prevention","volume":"27 10 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Safety Of BBIBP-CorV (Sinopharm) COVID-19 Vaccination In People With Multiple Sclerosis: A Report From Iran\",\"authors\":\"S. Nabavi, Mehrnoosh Mehrabani, L. Ghalichi, M. Nahayati, Mehran Ghaffari, F. Ashtari, S. E. Mohammadianinejad, S. Karimi, M. Salari, L. Faghani, S. Yazdanbakhsh, Abbas Najafian, M. Vosough\",\"doi\":\"10.14302/issn.2690-4837.ijip-22-4342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. \\nMethod: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated.\\nResults: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. \\nConclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them.\\n\\nKeywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety\",\"PeriodicalId\":325366,\"journal\":{\"name\":\"International Journal of Infection Prevention\",\"volume\":\"27 10 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infection Prevention\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14302/issn.2690-4837.ijip-22-4342\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infection Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14302/issn.2690-4837.ijip-22-4342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

伊朗于2020年3月开始接种SARS - CoV-2疫苗,多发性硬化症(pwMS)患者与其他高危人群一样,优先接种疫苗。到目前为止,在伊朗人群和高危人群(如pwMS)中使用的主要疫苗是BBIBP-CorV(国药)。方法:本调查于2021年7月至8月对520例pwMS患者进行了第一次或/和第二次接种后的安全性和可能的副作用评估。对接受了一剂或两剂国药疫苗的多发性硬化症患者进行了评估。结果:大约44%的接受国药的pwMS患者报告了轻微的副作用,而接受第二次剂量的患者中有60%报告了其副作用。所有的副作用都是在24小时内开始的,之后48-96小时内消退。没有严重的副作用或死亡的报道。副作用与年龄、残疾状况、一线或二线疾病调节药物(dmd)类型无相关性。只有一些副作用在疾病的进展形式中明显更高。结论:MS患者可以安全接种国药疫苗,轻微的副作用不应使患者感到害怕。关键词:国药BBIBP-CorV;多发性硬化症;减病药物
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Safety Of BBIBP-CorV (Sinopharm) COVID-19 Vaccination In People With Multiple Sclerosis: A Report From Iran
Introduction: Vaccination against SARS CoV-2 started on March 2020 in Iran and people with multiple sclerosis (pwMS) have a priority to be vaccinated in line of other high-risk population. Up to now, BBIBP-CorV (Sinopharm) is the main vaccine which have been used in Iranian population, and in high risk population such as pwMS. Method: In this survey, the safety and possible side effects of this vaccine after the first or/and second doses in 520 pwMS have been assessed from July to August 2021. MS Patients who have received one or two doses of Sinopharm vaccine were evaluated. Results: Around 44% of pwMS who received Sinopharm reported few minor side effects, whereas its side effect have been reported in 60% of patients who received the second dose. All side effects have begun within the first 24 hours and subsided between 48-96 hours afterward. No serious side effects or mortality have been reported. There was no correlation between the side effects and age, the disability status, and the type of first or second line DMDs (disease modifying drugs). Only some side effects were significantly higher in the progressive form of the disease. Conclusion: MS patients can receive Sinopharm vaccine safely and the minor side effects should not scare them. Keywords: Sinopharm BBIBP-CorV, multiple sclerosis, disease modifying drugs, safety
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信